Compositions and methods for treatment of hepatitis b
Lipid nanoparticles encapsulating Cas9-BE mRNA and gRNA address the limitations of CRISPR/Cas9 by precisely modifying HBV genotypes, including cccDNA, to reduce HBsAg secretion and achieve a functional cure for HBV.
Patent Information
- Application Number
- TW114133537
- Authority / Receiving Office
- TW · TW
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2024-09-02
- Filing Date
- 2025-09-02
- Publication Date
- 2026-07-01
AI Technical Summary
Current antiviral therapies for hepatitis B virus (HBV) fail to effectively target and destroy covalently closed circular DNA (cccDNA), leading to persistent infection and immunosuppressive effects, and existing CRISPR/Cas9 systems risk significant chromosomal rearrangements and deletions.
A composition comprising lipid nanoparticles encapsulating Cas9-BE mRNA and gRNA, utilizing base editors like SpRY-BE to modify HBV genotypes by converting C·G to T·A base pairs without inducing double-strand breaks, targeting multiple HBV genotypes with optimized gRNAs and Cas9 variants.
Reduces the risk of chromosomal rearrangements while effectively modifying HBV genotypes, including cccDNA, thereby potentially achieving a functional cure by reducing HBsAg secretion.